Update on the Pharmacologic Agents for Dyslipidemia / 임상당뇨병
Journal of Korean Diabetes
;
: 269-275, 2015.
Artigo
em Coreano
| WPRIM
| ID: wpr-726852
ABSTRACT
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Ácidos Graxos Ômega-3
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Pró-Proteína Convertases
/
Dislipidemias
/
Proteínas de Transferência de Ésteres de Colesterol
/
Prescrições
/
Ácidos Fíbricos
/
Ezetimiba
/
Niacina
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS